^
Association details:
| Biomarker: | IL3RA expression |
|---|---|
| Cancer: | Childhood B Acute Lymphoblastic Leukemia |
| Drug: | pivekimab sunirine (IMGN632) (DNA replication inhibitor, CD123-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia
Published date:
11/15/2022
Excerpt:
Two B-lineage ALL PDXs with moderate CD123 expression (one B-cell precursor, BCP; one mixed-lineage leukemia-rearranged, MLLr) were selected for a dose-response study, and 40 ALL PDXs...Of the 37 evaluable PDXs in the SMT, 29 scored objective responses (11/12 BCP, 2/3 Ph+, 8/8 Ph-like, 6/7 MLLr, 0/3 T-ALL, 2/4 ETP), with 26 PDXs attaining MCRs. Mouse EFS ranged from 6.8-379 days and was significantly greater in B-lineage PDXs (n=30) than T-lineage PDXs (n=7; p<0.0001)....IMGN632 exerted profound in vivo activity against pediatric ALL PDXs with varying CD123 expression levels, particularly those of B-lineage, inducing prolonged remissions at doses as low as 60 µg/kg.
DOI:
https://doi.org/10.1182/blood-2022-159867
